No Data
No Data
No Data
Fuji Pharma Sees FY Net Y6.19B
Fuji Pharma 9-Mos Net Y4.91B Vs Net Y1.98B
Fuji Pharma: Short message for the third quarter financial results (consolidated) for the period of September 2024 [Japanese standard]
INPEX, Sumitomo Riko, Suntory BF, and Kao (8th) (1375-5989).
*Please note that the above calendar is subject to change due to company circumstances. --------------------------------------- August 8th (Thursday) <1375> Yukiguni Maitake <1382> HOB <1439> Yasue Construction <1605> INPEX <1662> Petroleum Resources <167A> Ryosan Hiryo <1721> Comsys HD <1736> Autec <178>
Stocks that moved the day before, part 1: NexTone, FLN, Shibaura Mechatronics, etc.
Full year metal <7826> 4555 +135, with performance underperforming but dividend increase highly regarded. Kitanihon Bouseki <3409> 101 +3, sales contract for the world's first charge-free smart tracker developed by a subsidiary of Medirom, which is listed on NASDAQ. Amazia <4424> 552 +80, speculation that manga app usage will increase due to the spread of the novel coronavirus and expectation of intense heat. FLN <9241> 1969 +219, introduces shareholder benefits program with only 1.
Bronco B, SE H&I, Good Product Plan, etc.
<4503> Astellas Pharma fell sharply by 55 to 1642. Jefferies Securities downgraded its investment rating from "buy" to "hold" and lowered its target stock price from 2100 yen to 1700 yen. Sales forecasts for overactive bladder treatment Mirabegron, hot flush treatment Veoza, and geographic atrophy treatment Izervay have been downwardly revised, and annual revenue estimates for the next five years are expected to decrease by an average of 5%. The EBITDA estimate appears to be about 9% below consensus. <7
No Data